At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 722 enrolled
Drug / intervention
LEO 90100 aerosol foam +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris
In Brief
A Phase 3 clinical trial evaluating LEO 90100 aerosol foam and LEO 90100 aerosol foam vehicle for Psoriasis Vulgaris. Completed, enrolled 722 participants across 58 sites in 6 countries.
Detailed Summary
A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris. A 12-month, international, multi-centre, randomised, vehicle controlled, double-blind, 2-arm, parallel group trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesCanada, France, Germany, Poland, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartFeb 2017
Primary CompletionJun 2019
TodayJul 2026
First PostedSep 14, 2016
Enrollment StartFeb 15, 2017
Primary CompletionJun 26, 2019
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 9.8 years ago
Interventions
LEO 90100 aerosol foamdrug
LEO 90100 aerosol foam twice weekly
LEO 90100 aerosol foam vehicledrug
LEO 90100 aerosol foam vehicle twice weekly